Markets:

Overview

News

Currencies

International

Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

7.875 +0.185 (+2.41%)

Streaming Delayed Price Updated: 10:17 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Target To $200? Here Are 5 Other Price Target Changes For Thursday ↗

August 18, 2022

Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1%...

Via Benzinga

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 16, 2022

Via ACCESSWIRE

Earnings Scheduled For August 12, 2022 ↗

August 12, 2022

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

Via Benzinga

What 4 Analyst Ratings Have To Say About NeoGenomics ↗

August 10, 2022

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter:

Via Benzinga

NeoGenomics: Q2 Earnings Insights ↗

August 09, 2022

NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

August 09, 2022

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022

October 13, 2022

Via ACCESSWIRE

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

September 07, 2022

Via ACCESSWIRE

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022 ↗

August 26, 2022

Upgrades

Via Benzinga

Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock ↗

August 22, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022 ↗

August 22, 2022

Upgrades

Via Benzinga

NeoGenomics: Q2 Earnings Insights ↗

August 12, 2022

NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

NeoGenomics Announces Chief Executive Officer Appointment

July 21, 2022

Via ACCESSWIRE

NeoGenomics Announces Chief Executive Officer Appointment

July 21, 2022

Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board

From NeoGenomics, Inc.

Via AccessWire

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

July 15, 2022

FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...

From NeoGenomics, Inc.

Via AccessWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 27, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 24, 2022

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 24, 2022

From Law Offices of Frank R. Cruz

Via Business Wire

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

June 21, 2022

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms...

From NeoGenomics, Inc.

Via AccessWire

Lost Money in NeoGenomics, Inc.?

June 03, 2022

From Gibbs Law Group

Via Business Wire

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

June 03, 2022

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

From NeoGenomics, Inc.

Via AccessWire

Analyst Ratings for NeoGenomics ↗

June 03, 2022

Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

June 03, 2022

CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D

From NeoGenomics, Inc.

Via AccessWire

NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc. ↗

June 02, 2022

San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties.

Via SBWire

Lost Money in NeoGenomics, Inc.?

May 24, 2022

From Gibbs Law Group

Via Business Wire

Lost Money in NeoGenomics, Inc.?

May 16, 2022

From Gibbs Law Group

Via Business Wire

NeoGenomics Appoints Lynn Tetrault Interim CEO

May 16, 2022

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,...

From NeoGenomics, Inc.

Via AccessWire

Earnings Scheduled For May 13, 2022 ↗

May 13, 2022

Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.